Sada, Yvonne

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Zhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology

Hepatocellular Carcinoma Treatment and PrognosisCancer Immunotherapy and Biomarkers

Cited by 2,479

Hepatocellular carcinoma in the absence of cirrhosis in United States Veterans is associated with nonalcoholic fatty liver disease

Mittal, S., El-Serag, H. B., Sada, Y. H., Kanwal, F., Duan, Z., Temple, S., May, S. B., Kramer, J. R., Richardson, P. A., & Davila, J. A. (2016) · Clinical Gastroenterology and Hepatology

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 648

Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer

Walker, M., El‐Serag, H. B., Sada, Y., Mittal, S., Ying, J., Duan, Z., Richardson, P., Davila, J. A., & Kanwal, F. (2016) · Alimentary Pharmacology & Therapeutics

Hepatocellular Carcinoma Treatment and PrognosisLiver Disease Diagnosis and Treatment

Cited by 84